Compare Stocks: UG, IMUX, RFAI, and AARD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.06	$6.16	$3.35 ▼ $17.94	$110.71M	3.74	126,422 shs	71,469 shs
IMUX Immunic	$9.35	$13.75	$5.06 ▼ $17.43	$127.53M	1.41	365,555 shs	316,526 shs
RFAI RF Acquisition Corp II	$30.90 -5.7%	$26.40	$8.94 ▼ $73.00	$108.44M	1.16	17,288 shs	26,990 shs
UG United-Guardian	$7.08	$7.25	$5.58 ▼ $8.45	$32.50M	0.96	7,325 shs	2,151 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	-5.95%	-12.61%	-2.32%	-61.75%
IMUX Immunic	0.00%	-12.09%	-39.29%	-39.33%	-0.44%
RFAI RF Acquisition Corp II	0.00%	-22.40%	-40.64%	+179.85%	+190.23%
UG United-Guardian	0.00%	-1.80%	-0.98%	-0.84%	-7.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.06	$6.16	$3.35 ▼ $17.94	$110.71M	3.74	126,422 shs	71,469 shs
IMUX Immunic	$9.35	$13.75	$5.06 ▼ $17.43	$127.53M	1.41	365,555 shs	316,526 shs
RFAI RF Acquisition Corp II	$30.90 -5.7%	$26.40	$8.94 ▼ $73.00	$108.44M	1.16	17,288 shs	26,990 shs
UG United-Guardian	$7.08	$7.25	$5.58 ▼ $8.45	$32.50M	0.96	7,325 shs	2,151 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	-5.95%	-12.61%	-2.32%	-61.75%
IMUX Immunic	0.00%	-12.09%	-39.29%	-39.33%	-0.44%
RFAI RF Acquisition Corp II	0.00%	-22.40%	-40.64%	+179.85%	+190.23%
UG United-Guardian	0.00%	-1.80%	-0.98%	-0.84%	-7.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.42	Hold	$15.33	203.03% Upside
IMUX Immunic	3.00	Buy	$47.25	405.35% Upside
RFAI RF Acquisition Corp II	1.00	Sell	N/A	N/A
UG United-Guardian	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest UG, IMUX, RFAI, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$6.00
9/10/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
9/10/2026	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00
9/4/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/1/2026	IMUX Immunic	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/17/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/7/2026	RFAI RF Acquisition Corp II	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/29/2026	IMUX Immunic	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2026	UG United-Guardian	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$4.90 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	($0.55) per share	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A
UG United-Guardian	$10.55M	3.08	$0.48 per share	14.69	$2.44 per share	2.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-71.54%	-64.94%	N/A
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
UG United-Guardian	$2.11M	$0.54	13.11	N/A	N/A	22.01%	22.24%	19.12%	N/A

Latest UG, IMUX, RFAI, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A
8/7/2026	Q2 2026	RFAI RF Acquisition Corp II	N/A	$0.01	N/A	$0.01	N/A	N/A
8/7/2026	Q2 2026	UG United-Guardian	N/A	$0.16	N/A	$0.16	N/A	$3.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
RFAI RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
UG United-Guardian	$0.60	8.47%	-5.11%	111.11%	1 Years

Latest UG, IMUX, RFAI, and AARD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/14/2026	UG United-Guardian		$0.30	8.19%	7/28/2026	7/28/2026	8/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	12.63	12.63
IMUX Immunic	N/A	5.05	5.05
RFAI RF Acquisition Corp II	N/A	N/A	N/A
UG United-Guardian	N/A	7.32	6.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
IMUX Immunic	51.82%
RFAI RF Acquisition Corp II	N/A
UG United-Guardian	23.16%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
IMUX Immunic	5.49%
RFAI RF Acquisition Corp II	39.10%
UG United-Guardian	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	28	21.88 million	17.99 million	N/A
IMUX Immunic	95	13.64 million	12.90 million	Optionable
RFAI RF Acquisition Corp II	2	3.51 million	2.14 million	N/A
UG United-Guardian	25	4.59 million	3.26 million	Not Optionable

UG, IMUX, RFAI, and AARD Headlines

Recent News About These Companies

How United-guardian Inc. (UG) Affects Rotational Strategy Timing

September 24, 2026 | news.stocktradersdaily.comN

Upside Gold Announces September Investor Outreach Schedule

September 16, 2026 | thenewswire.comT

UG Q2 Earnings Rise Y/Y on Strong Cosmetic Ingredient Sales

August 14, 2026 | zacks.com

United-Guardian: Q2 Earnings Snapshot

August 7, 2026 | wtop.comW

United-Guardian Reports Second Quarter Results

August 7, 2026 | globenewswire.com

United-Guardian Insider Trading Activity | NASDAQ:UG | Benzinga

July 16, 2026 | benzinga.com

United-Guardian Declares Cash Dividend

July 16, 2026 | globenewswire.com

UG Outperforms Industry in 6 Months: Buy, Sell or Hold the Stock?

July 8, 2026 | zacks.com

Engages Danayi Capital Corp. To Provide Digital Marketing Services

June 12, 2026 | thenewswire.comT

Upside Gold Corp. Announces Closing of $5 Million Brokered Private Placement

June 12, 2026 | thenewswire.comT

Upside Gold Corp. Announces Closing of $5 Million Brokered Private Placement

June 12, 2026 | thenewswire.comT

Upside Gold Announces Fully Permitted Drill Program at the Kena Gold-Copper Project

May 27, 2026 | thenewswire.comT

United-Guardian Q1 Earnings Rise Y/Y on Strong Renacidin Demand

May 18, 2026 | zacks.com

United-Guardian, Inc. (UG) Shareholder/Analyst Call Transcript

May 13, 2026 | seekingalpha.com

Upside Gold Corp. Finalizes Acquisition of Strategic High-Grade Gold Claims Adjacent to the Kena Project

May 13, 2026 | thenewswire.comT

United-Guardian Reports First Quarter Results

May 8, 2026 | globenewswire.com

Upside Gold Corp. Signs LOI For Strategic Claims Adjacent To The Kena Property

April 27, 2026 | thenewswire.comT

Upside Gold Corp. Announces Grant Of Stock Options

April 9, 2026 | thenewswire.comT

United-Guardian 2025 Earnings Fall Y/Y Amid Weak Sales Trends

March 31, 2026 | zacks.com

United-Guardian: Q4 Earnings Snapshot

March 27, 2026 | khou.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UG, IMUX, RFAI, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$5.06 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$5.30 +0.24 (+4.64%)

As of 09/25/2026 07:30 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Immunic NASDAQ:IMUX

$9.35 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$9.30 -0.04 (-0.48%)

As of 09/25/2026 07:30 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

RF Acquisition Corp II NASDAQ:RFAI

$30.90 -1.86 (-5.66%)

Closing price 09/25/2026 03:58 PM Eastern

Extended Trading

$31.28 +0.39 (+1.26%)

As of 09/25/2026 07:42 PM Eastern

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.

United-Guardian NASDAQ:UG

$7.08 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$7.08 +0.00 (+0.07%)

As of 09/25/2026 04:10 PM Eastern

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and product development of cosmetic ingredients. The company was founded in 1942 and is based in Hauppauge, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UG, IMUX, RFAI, and AARD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UG, IMUX, RFAI, and AARD Earnings

Compare Dividends

Latest UG, IMUX, RFAI, and AARD Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UG, IMUX, RFAI, and AARD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UG, IMUX, RFAI, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Immunic NASDAQ:IMUX

RF Acquisition Corp II NASDAQ:RFAI

United-Guardian NASDAQ:UG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools